UCB INC Company Profile

✉ Email this page to a colleague

UCB INC has forty-two approved drugs.

There are thirty-five US patents protecting UCB INC drugs.

There are four hundred and ninety-three patent family members on UCB INC drugs in fifty-two countries and forty-five supplementary protection certificates in fifteen countries.

International Patents:	493
US Patents:	35
Tradenames:	29
Ingredients:	24
NDAs:	42
Drug Master File Entries:	1
Patent Litigation for UCB INC:	See patent lawsuits for UCB INC

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-004	Oct 28, 2008	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Ucb Inc	NIRAVAM	alprazolam	TABLET, ORALLY DISINTEGRATING;ORAL	021726-003	Jan 19, 2005		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-001	Oct 17, 2023		RX	Yes	Yes	10,208,089	⤷ Sign Up		Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-002	Nov 30, 1999	4,837,223	⤷ Sign Up
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;ORAL	205838-001	May 12, 2016	8,492,416	⤷ Sign Up
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016	8,492,416	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	10 mg/mL, 20 mL	➤ Subscribe	2016-06-30
➤ Subscribe	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	➤ Subscribe	2005-12-27
➤ Subscribe	Tablets	1000 mg	➤ Subscribe	2007-01-24
➤ Subscribe	Tablets	50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2012-10-29
➤ Subscribe	Extended-release Tablets	1000 mg	➤ Subscribe	2011-01-07
➤ Subscribe	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg	➤ Subscribe	2004-01-15
➤ Subscribe	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr	➤ Subscribe	2013-11-26
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2012-10-29

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0888289	C300376	Netherlands	⤷ Sign Up	PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829
0454511	SPC/GB99/008	United Kingdom	⤷ Sign Up	PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
1452524	530	Finland	⤷ Sign Up
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.